Ordinary Fully Paid Deferred Settlement (AU:IMUDA) — Market Cap & Net Worth
Market Cap & Net Worth: Ordinary Fully Paid Deferred Settlement (IMUDA)
Ordinary Fully Paid Deferred Settlement (AU:IMUDA) has a market capitalization of $2.57K (AU$3.63K) as of June 20, 2026. Listed on the AU stock exchange, this Australia-based company holds position #31677 globally and #1821 in its home market, demonstrating a -8.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ordinary Fully Paid Deferred Settlement's stock price AU$0.40 by its total outstanding shares 9073 (9.07K).
Ordinary Fully Paid Deferred Settlement Market Cap History: 2025 to 2025
Ordinary Fully Paid Deferred Settlement's market capitalization history from 2025 to 2025. Data shows growth from $2.57K to $2.57K (0.00% CAGR).
Ordinary Fully Paid Deferred Settlement Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ordinary Fully Paid Deferred Settlement's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMUDA by Market Capitalization
Companies near Ordinary Fully Paid Deferred Settlement in the global market cap rankings as of June 20, 2026.
Key companies related to Ordinary Fully Paid Deferred Settlement by market ranking:
- PTT OIL+RET.BUS.-FOR-BA10 (F:7F8): Ranked #31668 globally with a market cap of $3.14K USD ( €2.69K EUR).
- Ordinary Fully Paid Deferred Settlement (AU:IXRDB): Ranked #31669 globally with a market cap of $3.04K USD ( AU$4.29K AUD).
- An Pha Petroleum Group JSC (VN:ASP): Ranked #31678 globally with a market cap of $2.55K USD ( ₫67.07 Million VND).
- CI Com SA (SW:CIE): Ranked #31679 globally with a market cap of $2.55K USD ( CHF2.01K CHF).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31668 | PTT OIL+RET.BUS.-FOR-BA10 | F:7F8 | $3.14K | €0.30 |
| #31669 | Ordinary Fully Paid Deferred Settlement | AU:IXRDB | $3.04K | AU$0.46 |
| #31678 | An Pha Petroleum Group JSC | VN:ASP | $2.55K | ₫7300.00 |
| #31679 | CI Com SA | SW:CIE | $2.55K | CHF0.21 |
Ordinary Fully Paid Deferred Settlement Historical Marketcap From 2025 to 2025
Between 2025 and today, Ordinary Fully Paid Deferred Settlement's market cap moved from $2.57K to $ 2.57K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | AU$2.57K | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of Ordinary Fully Paid Deferred Settlement was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.57K USD |
| MoneyControl | $2.57K USD |
| MarketWatch | $2.57K USD |
| marketcap.company | $2.57K USD |
| Reuters | $2.57K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ordinary Fully Paid Deferred Settlement
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more